Please login to the form below

Not currently logged in
Email:
Password:

GSK strikes deal with Dr. Reddy's

GSK has entered into an agreement with Dr. Reddy's Laboratories to develop and market selected products across an extensive number of emerging markets, excluding India

GlaxoSmithKline (GSK) has entered into an agreement with Dr. Reddy's Laboratories to develop and market selected products across an extensive number of emerging markets, excluding India.

Under the agreement, GSK will gain exclusive access to Dr. Reddy's portfolio and future pipeline of more than 100 branded pharmaceuticals in fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.

The products will be manufactured by Dr. Reddy's and licensed and supplied by GSK in various countries in Africa, the Middle East, Asia Pacific and Latin America.

In certain markets, products will be co-marketed by GSK and Dr. Reddy's. Under the terms of the agreement, revenues will be reported by GSK and shared with Dr. Reddy's as per the agreed terms.

According to GV Prasad, vice chairman and CEO, Dr. Reddy's: "We hope to take our purpose of providing affordable and innovative medicines to a much wider population through this partnership."

Abbas Hussain, president for emerging markets at GSK said: "This is another significant step forward in our strategy to grow and diversify GSK's business in emerging markets."

15th June 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics